Powell Lynne 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Jan 23, 2019
Insider Transaction Report
Form 4
Powell Lynne
Senior VP - CCO
Transactions
- Exercise/Conversion
Common Stock
2019-01-18$3.22/sh+2,000$6,440→ 2,000 total - Sale
Common Stock
2019-01-18$9.40/sh−2,000$18,800→ 0 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2019-01-18−2,000→ 91,427 totalExercise: $3.22From: 2017-05-23Exp: 2026-05-23→ Common Stock (2,000 underlying)
Footnotes (1)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018.